John Strickler, MD

John H. Strickler, MD, details the impetus for evaluating the novel c-Met–directed ADC Temab-A in refractory metastatic colorectal cancer.

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

John H. Strickler, MD, details the rationale for evaluating telisotuzumab adizutecan in advanced gastric/GEJ cancer.

John H. Strickler, MD, discusses the rationale for developing telisotuzumab adizutecan in MET gene–amplified advanced gastric cancer.

Dr Strickler discusses the challenges of targeting RAS alterations in pancreatic cancer and efforts to improve pancreatic cancer screening rates.

John H. Strickler, MD, discusses the role of biomarker testing in metastatic pancreatic cancer.

John H. Strickler, MD, discusses the efficacy and safety of telisotuzumab adizutecan in patients with MET gene–amplified gastric/GEJ cancer.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

John H. Strickler, MD, discusses the significance of the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer.

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

John H. Strickler, MD, discusses the rationale for the phase 2/3 MOUNTAINEER-02 trial in HER2-positive gastric/gastroesophageal junction cancer.

John Strickler, MD, assistant professor of medicine, Duke Cancer Institute, discusses genomic variants that can be detected by liquid biopsies in patients with gastrointestinal cancers.

John Strickler, MD, assistant professor of medicine at Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses therapies for rare variants of relapsed/refractory colorectal cancer.

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses the value of liquid biopsies in the treatment of patients with colorectal cancer (CRC).

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses applications for liquid biopsies in gastrointestinal cancer.

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses improvements in the treatment of metastatic colorectal cancer.